Sep 11, 2026 08:01AM
Sep 11, 2026 08:00AM
Aug 14, 2026 08:00AM
Aug 14, 2026 08:00AM
Jul 7, 2026 08:03AM
Jul 7, 2026 08:00AM
Jun 30, 2026 08:01AM Allarity gets U.S. patent for stenoparib companion diagnostic
Jun 30, 2026 08:00AM
Jun 18, 2026 08:00AM
Jun 18, 2026 08:00AM
May 15, 2026 04:30PM
May 5, 2026 08:00AM
May 5, 2026 08:00AM
Apr 27, 2026 08:00AM Allarity receives patent allowance for stenoparib diagnostic test
Apr 27, 2026 08:00AM
Apr 21, 2026 08:02AM
Apr 21, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 6, 2026 08:01AM
Mar 6, 2026 08:00AM Allarity Therapeutics closes $20 million debt financing round
Mar 6, 2026 08:00AM
Mar 6, 2026 08:00AM
Feb 18, 2026 08:15AM
Feb 18, 2026 08:15AM
Feb 3, 2026 08:00AM
Feb 3, 2026 08:00AM
Dec 31, 2025 08:00AM Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
Nov 14, 2025 09:00AM
Sep 22, 2025 08:01AM
Sep 22, 2025 08:00AM
Aug 26, 2025 08:00AM
Aug 26, 2025 08:00AM
Jun 2, 2025 08:00AM
Jun 2, 2025 08:00AM Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
May 9, 2025 04:05PM
Apr 25, 2025 08:01AM
Apr 25, 2025 08:00AM
Mar 31, 2025 04:05PM
Mar 13, 2025 08:33AM
Mar 13, 2025 08:30AM
Mar 6, 2025 08:00AM Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Feb 24, 2025 08:00AM
Feb 6, 2025 08:01AM
Feb 6, 2025 08:00AM
Jan 30, 2025 08:06AM
Jan 30, 2025 08:00AM
Nov 18, 2024 08:03AM
Nov 18, 2024 08:00AM Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Nov 14, 2024 08:00AM

330,739 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All